EA028448B1 - Способ снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом, и набор для титрования для снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом - Google Patents

Способ снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом, и набор для титрования для снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом Download PDF

Info

Publication number
EA028448B1
EA028448B1 EA201301024A EA201301024A EA028448B1 EA 028448 B1 EA028448 B1 EA 028448B1 EA 201301024 A EA201301024 A EA 201301024A EA 201301024 A EA201301024 A EA 201301024A EA 028448 B1 EA028448 B1 EA 028448B1
Authority
EA
Eurasian Patent Office
Prior art keywords
interferon
week
patient
titration
titration kit
Prior art date
Application number
EA201301024A
Other languages
English (en)
Russian (ru)
Other versions
EA201301024A1 (ru
Inventor
Аарон Дейкин
Original Assignee
Байоджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Инк. filed Critical Байоджен Инк.
Publication of EA201301024A1 publication Critical patent/EA201301024A1/ru
Publication of EA028448B1 publication Critical patent/EA028448B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
EA201301024A 2011-03-15 2012-03-15 Способ снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом, и набор для титрования для снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом EA028448B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (2)

Publication Number Publication Date
EA201301024A1 EA201301024A1 (ru) 2014-03-31
EA028448B1 true EA028448B1 (ru) 2017-11-30

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301024A EA028448B1 (ru) 2011-03-15 2012-03-15 Способ снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом, и набор для титрования для снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125809A1 (en) * 2011-03-15 2012-09-20 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1226092A1 (zh) * 2014-01-09 2017-09-22 Kyushu University, National University Corporation 制备小胶质细胞的方法
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
ES2712469T3 (es) * 2003-01-30 2019-05-13 Becton Dickinson Co Soporte con escudo de seguridad para un dispositivo de administración de fármaco
BRPI0510526A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2012125809A1 (en) * 2011-03-15 2012-09-20 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANON.: "Betaferon", 8 February 2010 (2010-02-08), pages 1 - 12, XP002677736, Retrieved from the Internet <URL:http://www.pharmaline.co.il/images/newsletterregistration/bayer/betaferondoctor.pdf> [retrieved on 20120613] *
ANON.: "Instructions for use: Avostartgrip Titration Kit", BIOGEN IDEC INC., 1 February 2012 (2012-02-01), pages 1 - 9, XP002677737, Retrieved from the Internet <URL:http://www.avonex.com/pdfs/guides/Avostartgrip_IFU.pdf> [retrieved on 20120613] *
ANON.: "Medication Guide Appendix: Instructions for Preparing and Giving a Dose with an Avonex Prefilled Syringe", 1 August 2010 (2010-08-01), pages 1 - 6, XP002677734, Retrieved from the Internet <URL:http://www.avonex.com/pdfs/guides/Liquid_appendix_I61023.pdf> [retrieved on 20120613] *
BRANDES D W; BIGLEY K; HORNSTEIN W; COHEN H; AU W; SHUBIN R: "Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: A pilot study", CURRENT MEDICAL RESEARCH AND OPINION, INFORMA HEALTHCARE, GB, vol. 23, no. 7, 1 July 2007 (2007-07-01), GB, pages 1667 - 1672, XP009160129, ISSN: 0300-7995, DOI: 10.1185/030079907X210741 *
FROHMAN ELLIOT; PHILLIPS TED; KOKEL KRISTEN; VAN PELT JERRY; O'LEARY SHIRLEY; GROSS SHELLY; HAWKER KATHLEEN; RACKE MICHAEL: "Disease-modifying therapy in multiple sclerosis: strategies for optimizing management", NEUROLOGIST, WLLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 8, no. 4, 1 July 2002 (2002-07-01), US, pages 227 - 236, XP009160126, ISSN: 1074-7931, DOI: 10.1097/00127893-200207000-00003 *
HURWITZ, B.J. ; JEFFERY, D. ; ARNASON, B. ; BIGLEY, K. ; COYLE, P. ; GOODIN, D. ; KABA, S. ; KIRZINGER, S. ; LYNCH, S. ; MANDLER, : "Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 @?g QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study", CLINICAL THERAPEUTICS., EXCERPTA MEDICA, PRINCETON, NJ., US, vol. 30, no. 6, 1 June 2008 (2008-06-01), US, pages 1102 - 1112, XP022938732, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2008.06.013 *
J PHILLIPS, GEORGE RICE, ELLIOT FROHMAN, LUC VANDE GAER, THOMAS SCOTT, JUDITH HAAS, ERIC EGGENBERGER, MARK FREEDMAN, WILLIAM STUAR: "A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosis", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, vol. 26, no. 4, 1 April 2004 (2004-04-01), pages 511 - 521, XP055029619, ISSN: 01492918, DOI: 10.1016/S0149-2918(04)90053-7 *
MATSON M A; ZIMMERMAN T R; TUCCILLO D; TANG Y; DEYKIN A: "Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation", CURRENT MEDICAL RESEARCH AND OPINION, INFORMA HEALTHCARE, GB, vol. 27, no. 12, 1 December 2011 (2011-12-01), GB, pages 2271 - 2278, XP009160128, ISSN: 0300-7995, DOI: 10.1185/03007995.2011.630720 *
RICE G P A; EBERS G C; LUBLIN F D; KNOBLER R L: "Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 52, no. 9, 1 June 1999 (1999-06-01), US, pages 1893 - 1895, XP002677735, ISSN: 0028-3878, DOI: 10.1212/WNL.52.9.1893 *
WROE: "Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis.", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, CAMBRIDGE MEDICAL PUBLICATIONS LTD., vol. 33, no. 3, 1 January 2005 (2005-01-01), pages 309 - 318, XP055029629, ISSN: 03000605, DOI: 10.1177/147323000503300306 *

Also Published As

Publication number Publication date
CY1120176T1 (el) 2018-12-12
MX2013010507A (es) 2014-04-30
US20220280610A1 (en) 2022-09-08
HUE036931T2 (hu) 2018-08-28
IL228425A (en) 2017-08-31
CN103702680A (zh) 2014-04-02
EP2686002B1 (en) 2018-01-24
SMT201800221T1 (it) 2018-07-17
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
KR102050339B1 (ko) 2019-11-29
SI2686002T1 (en) 2018-06-29
MX359947B (es) 2018-10-17
WO2012125809A1 (en) 2012-09-20
NZ712273A (en) 2016-09-30
US9198955B2 (en) 2015-12-01
KR20140038383A (ko) 2014-03-28
BR112013023609A2 (pt) 2016-12-06
ZA201306933B (en) 2016-07-27
ES2666850T3 (es) 2018-05-08
US20250276042A1 (en) 2025-09-04
PT2686002T (pt) 2018-04-23
US10500254B2 (en) 2019-12-10
JP2014508174A (ja) 2014-04-03
JP6279905B2 (ja) 2018-02-14
US20120237479A1 (en) 2012-09-20
AU2012229104A1 (en) 2013-10-03
LT2686002T (lt) 2018-05-10
EA201301024A1 (ru) 2014-03-31
CA2846786C (en) 2022-05-17
EP2686002A1 (en) 2014-01-22
JP2018030847A (ja) 2018-03-01
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
AU2012229104B2 (en) 2017-03-16
HRP20180621T1 (hr) 2018-07-27
DK2686002T3 (en) 2018-04-30
PL2686002T3 (pl) 2018-10-31
SG193446A1 (en) 2013-10-30
NZ616536A (en) 2015-10-30
US20170360890A1 (en) 2017-12-21
IL228425A0 (en) 2013-12-31
US20160101157A1 (en) 2016-04-14
JP6522069B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
US20250276042A1 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP2442832B1 (en) Compositions and methods for treatment of multiple sclerosis
ZA200700524B (en) Methods of healing wounds by administering human IL-18
AU776181B2 (en) Combined treatment of multiple sclerosis
NZ616536B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1192473A (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1192473B (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ712273B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment